Abstract
For almost two decades, Tc-99m pyrophosphate has been the preferred infarct-avid imaging agent in nuclear cardiology. More recently, Indium-III- and Tc-99m-labeled antimyosin monoclonal antibody imaging have been extensively investigated. Although In-III antimyosin is not yet available in North America, this radioimmunoscintigraphic procedure is very promising for detection of both Q-wave and non-Q-wave myocardial infarction, especially when other standard diagnostic modalities fail to be contributive. When appropriately applied, radionuclide imaging with infarct-avid agents may provide very helpful clinical information.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
